North America Residual DNA Testing Market (2025-2030)
The North America Residual DNA Testing Market was valued at $111.2 Million in 2025 and projected to reach to $149.3 Million by 2030, representing a compound annual growth rate of 6.1%. North America's residual DNA testing market benefits from a well-established regulatory environment and advanced pharmaceutical manufacturing ecosystem.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
North America Residual DNA Testing Market Trends and Insights
- North America's mature healthcare infrastructure and regulatory framework support steady adoption of residual DNA testing across clinical laboratories, pharmaceutical manufacturing, and biopharmaceutical quality assurance.
- The region benefits from stringent contamination control requirements and increasing investment in advanced diagnostic capabilities throughout the forecast period. In North America, residual DNA testing demand is driven by pharmaceutical and biotechnology companies seeking to meet regulatory compliance standards and ensure product safety.
- North America's emphasis on quality control in drug manufacturing and the region's robust reimbursement landscape create favorable conditions for market expansion.
- Between 2025 and 2030, North America is expected to maintain its position as a significant market, supported by ongoing technological advancements and heightened awareness of contamination risks in biopharmaceutical production..
Key Market Statistics
- CAGR (2025-2030) 6.1% CAGR
- Market Size, 2025 ~USD 111.2 Million
- Forecast, 2030 ~USD 149.3 Million
- Geography North America
North America Residual DNA Testing Market Overview
Market Leadership :
North America commands the largest share of the global residual DNA testing market, driven by the US market valued at $75.8 million in 2025, representing 68% of the regional market.
Regulatory Compliance Driver :
Stringent FDA and Health Canada regulations mandate residual DNA testing in biopharmaceutical manufacturing, creating consistent demand across clinical laboratories and pharmaceutical quality assurance operations.
Steady Growth Trajectory :
The North American market expands at 6.1% CAGR from 2025 to 2030, reaching $149.3 million, reflecting mature adoption and integration into established quality control protocols.
Advanced Infrastructure :
Mature healthcare infrastructure, sophisticated laboratory networks, and high investment in biopharmaceutical R&D support widespread implementation of residual DNA testing technologies across the region.
North America Residual DNA Testing Market Dynamics
- The region's dominance is sustained by stringent quality standards from the FDA and Health Canada, which mandate residual DNA testing in gene therapy, viral vector production, and biopharmaceutical manufacturing.
- The US market, as the primary growth engine, continues to expand due to increasing biopharmaceutical development and heightened focus on product safety and efficacy. Looking ahead to 2030, the North American market will experience steady growth driven by technological advancements in testing methodologies, rising adoption of personalized medicine, and expanding clinical applications.
- Canada's emerging biotech sector and the US's continued investment in innovative therapeutics will sustain market expansion.
- However, growth rates remain moderate compared to global markets, reflecting the region's mature market status and already-high baseline adoption of residual DNA testing protocols..
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Pharmaceuticals
- Bioreactors
- Analytical Testing
- Bioanalytical Testing Services
- Cell Counters
- Data Management Services
- Thermo Fisher Scientific Inc.
- Merck KGaA
- SANOFI
- Pfizer Inc.
- NOVARTIS
Key Takeaways
- North America's residual DNA testing market reaches $111.2 million in 2025 with projected growth to $149.3 million by 2030.
- North America's 6.1% CAGR reflects steady, regulated market expansion driven by pharmaceutical quality assurance requirements.
- North America's stringent regulatory environment and advanced manufacturing standards support consistent demand for residual DNA testing.
- North America's biopharmaceutical sector investment and contamination control focus position the region as a stable, mature market through 2030.
Residual DNA Testing Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | CELL & GENE THERAPY (Application) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 16.4% from 2025 to 2030 |
| Largest Segment | POLYMERASE CHAIN REACTION (Technology) |
| Market Size Base Year (Billions) | ~USD 0.17 (2025) |
| Revenue Forecast (Billions) | ~USD 0.37 (2030) |
| Segments Covered | Offering, Type, Test Type, Technology, Application, End User |
North America Residual DNA Testing Market Report Segmentation
6 segment dimensions are covered across the global market.
By Offering
- Products
- Services
By Type
- Consumables
- Instruments & Software
By Test Type
- Bulk Lot Release Testing
- Final Product Release Testing
- Raw Material Testing
By Technology
- Dna Probe Hybridization
- Other Technologies
- Polymerase Chain Reaction
- Threshold Assays
By Application
- Cell & Gene Therapy
- Monoclonal Antibodies
- Other Applications
- Vaccines
By End User
- Academic & Research Institutes
- Cros & Cdmos
- Pharmaceutical & Biopharmaceutical Companies
- Pharmaceutical & Biotechnology Companies
Target Audience
- Biopharmaceutical Manufacturers : Require residual DNA testing data to ensure compliance with FDA/Health Canada regulations, optimize manufacturing quality control processes, and validate gene therapy and viral vector production safety.
- Clinical Laboratory Operators : Need market insights to expand testing service offerings, understand demand trends across North America, and invest in advanced residual DNA detection technologies and equipment.
- Diagnostic & Testing Equipment Vendors : Utilize market data to identify growth opportunities in the US and Canadian markets, develop region-specific product solutions, and establish partnerships with pharmaceutical quality assurance teams.
- Regulatory & Quality Assurance Professionals : Require comprehensive market intelligence to stay informed on compliance requirements, benchmark testing protocols against industry standards, and justify investments in residual DNA testing infrastructure.
- Healthcare Investment & Strategy Consultants : Need detailed North American market analysis to advise clients on market entry, acquisition opportunities, and strategic positioning within the biopharmaceutical quality assurance sector.
Key Companies in the North America Residual DNA Testing Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Consumables (assay kits, reagents, plastics),Instruments (PCR, qPCR, automation),Software & informatics, |
| CHARLES RIVER LABORATORIES | United States | Public Company | Consumables (assay reagents, kits within services),Instruments & Software (PCR and data platforms used in labs),Services – Raw Material Testing, |
| MERCK KGAA | United States | Public Company | Consumables (reagents, kits, assay components),Instruments,Software & Services (including CDMO/CRO testing support), |
| MARAVAI LIFESCIENCES | United States | Public Company | Consumables,Instrument & Software,Services, |
| EUROFINS SCIENTIFIC | Luxembourg | Public Company | Consumables,Instrument & Software,PCR-based Testing Services, |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Consumables,Instruments,Software & Informatics, |
| QIAGEN | Netherlands | Public Company | Consumables (sample prep, PCR, assays),Instruments (PCR, sample prep, QC),Software & Bioinformatics, |
| FUJIFILM CORPORATION | Japan | Public Company | Consumables (reagents, kits, media-linked components),Instruments & Software (PCR platforms, analytics, workflow tools),PCR-based Testing Services (CDMO-integrated), |
| SGS SOCIÉTÉ GéNéRALE DE SURVEILLANCE SA. | Switzerland | Public Company | Consumables-linked testing services,Instrument & software-enabled testing services,PCR-based residual DNA testing (all test types), |
| REVVITY | United States | Public Company | Consumables (reagents, assay kits, cartridges),Instruments,Software & Services, |
| INTERTEK GROUP PLC | United Kingdom | Public Company | Consumables,Instruments & Software,PCR-based Testing Services, |
| SARTORIUS AG | United States | Public Company | Consumables (filters, reagents, lab plastics linked to residual DNA workflows),Instruments (bioreactors, filtration systems, analytical platforms used in DNA-controlled processes),Software & data analytics (lab data, PAT, and QC integration), |
| LONZA | Switzerland | Public Company | Consumables,Instruments & Software,PCR-based Testing Services, |
THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific Inc. is a leading global provider of life sciences solutions, founded in 1956 and headquartered in the United States. With 125,000 employees, the company operates as a public corporation serving research, diagnostics, and bioproduction markets worldwide.
CHARLES RIVER LABORATORIES
Charles River Laboratories is a contract research organization founded in 1947, providing preclinical and clinical laboratory services to the pharmaceutical and biotechnology industries. The U.S.-based public company employs 19,000 people and supports drug development and safety testing globally.
MERCK KGAA
Merck KGaA is a diversified science and technology company founded in 1668, operating as a public company with 59,077 employees across the United States and globally. The company serves the pharmaceutical, life sciences, and performance materials sectors.
MARAVAI LIFESCIENCES
Maravai LifeSciences is a U.S.-based public company founded in 2014, specializing in critical reagents and services for the life sciences industry. With 416 employees, the company supports vaccine development, gene therapy, and molecular diagnostics.
EUROFINS SCIENTIFIC
Eurofins Scientific is a Luxembourg-based public company founded in 1987, operating a global network of laboratories with 65,694 employees. The company provides testing and analytical services across pharmaceutical, food, environmental, and consumer product sectors.
BIO-RAD LABORATORIES, INC.
Bio-Rad Laboratories, Inc. is a U.S. public company founded in 1952, manufacturing and distributing life science research and clinical diagnostics products. With 7,450 employees, the company serves research institutions, hospitals, and laboratories worldwide.
QIAGEN
QIAGEN is a Netherlands-based public company founded in 1984, specializing in sample and assay technologies for molecular diagnostics and life sciences research. The company employs 5,500 people and serves clinical, pharmaceutical, and academic markets globally.
FUJIFILM CORPORATION
Fujifilm Corporation is a Japanese multinational public company founded in 1934, with 73,526 employees operating across imaging, information, and life sciences divisions. The company provides diagnostic imaging, pharmaceutical, and biotechnology solutions worldwide.
SGS SOCIÉTÉ GéNéRALE DE SURVEILLANCE SA.
SGS Société Générale de Surveillance SA. is a Switzerland-based public company founded in 1878, employing 83,000 people in inspection, verification, testing, and certification services. The company serves industries including pharmaceuticals, food, and consumer goods globally.
REVVITY
Revvity is a U.S.-based public company founded in 1937, providing analytical instruments, software, and services for research and diagnostics. With 11,000 employees, the company supports life sciences, diagnostics, and environmental testing applications.
INTERTEK GROUP PLC
Intertek Group PLC is a United Kingdom-based public company founded in 1885, employing 45,425 people in testing, inspection, and certification services. The company serves industries including pharmaceuticals, chemicals, and consumer products across the globe.
SARTORIUS AG
Sartorius AG is a U.S.-based public company founded in 1870, manufacturing laboratory and bioprocess equipment with 14,242 employees. The company provides filtration, weighing, and bioanalytical solutions for pharmaceutical and life sciences applications.
LONZA
Lonza is a Switzerland-based public company founded in 1897, employing 20,000 people in pharmaceutical and biotechnology manufacturing and services. The company specializes in custom development and manufacturing, cell therapy, and specialty ingredients.
Countries within North America - compare and drill down
| Country | 2025 size (native) |
|---|---|
| US | USD 75.8 Million |
| Canada | USD 17.1 Million |
Country market size visualization
Reasons to Buy this Report
- Market Size & Valuation Data : Access precise market valuations for North America ($111.2M in 2025) and country-level breakdowns including the US ($75.8M) and Canada ($17.1M), enabling accurate budget allocation and investment decisions.
- Regulatory Landscape Insights : Understand FDA and Health Canada compliance requirements driving residual DNA testing adoption, helping manufacturers align quality assurance strategies with regional regulatory mandates.
- Growth Forecasting & CAGR Analysis : Leverage 6.1% regional CAGR projections through 2030 to forecast market expansion, identify growth opportunities, and plan capacity investments in testing infrastructure and services.
- Competitive Positioning : Benchmark your organization against the North American market's mature adoption landscape, identify underserved segments, and develop targeted strategies for clinical laboratories and biopharmaceutical manufacturers.
- Strategic Market Intelligence : Gain actionable insights into North America's advanced healthcare infrastructure, pharmaceutical manufacturing trends, and quality control priorities to inform product development and market entry strategies.
Frequently asked questions
What is the current market size of residual DNA testing in North America?
The North America residual DNA testing market is valued at $111.2 million in 2025 and is expected to reach $149.3 million by 2030.
What is the growth rate for residual DNA testing in North America?
North America's residual DNA testing market is growing at a compound annual growth rate of 6.1% from 2025 to 2030.
What drives demand for residual DNA testing in North America?
North America's demand is driven by pharmaceutical and biotechnology companies' need to meet regulatory compliance, ensure product safety, and maintain stringent quality control standards in biopharmaceutical manufacturing.
Which sectors in North America use residual DNA testing most?
North America's primary users include pharmaceutical manufacturers, biotechnology companies, clinical laboratories, and biopharmaceutical quality assurance departments focused on contamination prevention.
How does North America's market compare to global trends?
North America's 6.1% CAGR represents a more conservative growth trajectory compared to the global market's 16.4% CAGR, reflecting North America's mature, regulated market status.
RESEARCH METHODOLOGY
This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global residual DNA testing market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
Secondary research was used primarily to identify & collect information for the extensive, technical, market-oriented, and commercial study. The secondary sources used for this study include annual reports, SEC filings, investor presentations, World Health Organization (WHO), United States Food and Drug Administration (US FDA), National Center for Biotechnology Information (NCBI), Health Canada, European Medicines Agency (EMA), and Centers for Disease Control and Prevention (CDC). These sources also obtained key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative & quantitative information and assess the prospects of the market. Various primary sources from both the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the residual DNA testing market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Data Triangulation
The total market was split into several segments and subsegments after arriving at the overall market size from the estimation process. Where applicable, data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Residual DNA testing involves the detection and quantification of DNA impurities from host cells present in biopharmaceutical products. This testing is a critical component in the quality assurance of biologics, as it assesses the levels of residual DNA that may remain in the final product, bulk intermediates, or raw materials post-purification. The market for residual DNA testing encompasses a diverse array of analytical tools and services tailored to meet stringent regulatory requirements. Compliance with guidelines established by the FDA, WHO, and GxP standards necessitates a thorough evaluation of host cell DNA to mitigate risks and ensure safety and efficacy in biologics. This regulatory landscape makes residual DNA testing a vital focus area in the development and manufacturing of biologic products, emphasizing the need for precision and reliability in these assessments.
Stakeholders
- Pharmaceutical & biotechnology companies
- Academic researchers and government research organizations
- Private research institutes
- Custom residual DNA testing service providers
- Contract development & manufacturing organizations (CDMOs)
- Life Science Companies
- Contract research organizations (CROs)
- Market research & consulting firms
- Venture capitalists
Report Objectives
- To define, describe, and forecast the global residual DNA testing market by offering, technology, test type, application, end user (product), end user (service), and region
- To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, and opportunities)
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall residual DNA testing market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- Track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the residual DNA testing market.
- To analyze and provide funding & investment activities, brand/product comparative analysis, and vendor valuation & financial metrics of the residual DNA testing market.
Get the Full Residual DNA Testing Market Report
Full forecast, segment splits, and company analysis for all Residual DNA Testing Market.
- Rest Of Europe Residual DNA Testing Market
- Rest Of Asia Pacific Residual DNA Testing Market
- Rest Of Latin America Residual DNA Testing Market
- Rest Of GCC Countries Residual DNA Testing Market
- Saudi Arabia Residual DNA Testing Market
- GCC Countries Residual DNA Testing Market
- Rest Of Middle East Residual DNA Testing Market
- Canada Residual DNA Testing Market
- US Residual DNA Testing Market
- Germany Residual DNA Testing Market
- UK Residual DNA Testing Market
- France Residual DNA Testing Market
- Italy Residual DNA Testing Market
- Spain Residual DNA Testing Market
- China Residual DNA Testing Market
- Japan Residual DNA Testing Market
- India Residual DNA Testing Market
- South Korea Residual DNA Testing Market
- Australia Residual DNA Testing Market
- Brazil Residual DNA Testing Market
- Mexico Residual DNA Testing Market
- UAE Residual DNA Testing Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
